• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 10:04:35 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PPBT alert in real time by email
    SC 13G/A 1 tm216476d43_sc13ga.htm SCHEDULE 13G/A

     

    CUSIP No: 74638P109

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Purple Biotech Ltd. (formerly Kitov Pharma Ltd.)

    (Name of Issuer)

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    74638P109
    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No: 74638P109

     

    (1) NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands

     

    NUMBER OF   (5) SOLE VOTING POWER
           
    SHARES     0
           
    BENEFICIALLY   (6) SHARED VOTING POWER **
           
    OWNED BY     

    1,348,889

         
    EACH      
      (7) SOLE DISPOSITIVE POWER
    REPORTING      
        0
    PERSON WITH      
      (8) SHARED DISPOSITIVE POWER **
           
         

    1,348,889

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    1,348,889

       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        0.8%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 74638P109

     

    (1) NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware

     

    NUMBER OF   (5) SOLE VOTING POWER
           
    SHARES     0
           
    BENEFICIALLY   (6) SHARED VOTING POWER **
           
    OWNED BY    

    1,348,889

         
    EACH      
      (7) SOLE DISPOSITIVE POWER
    REPORTING      
        0
    PERSON WITH      
      (8) SHARED DISPOSITIVE POWER **
           
         

    1,348,889

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    1,348,889

       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        0.8%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 74638P109

     

    Item 1.

     

    (a) Name of Issuer

     

    Purple Biotech Ltd. (formerly Kitov Pharma Ltd.)(the “Company”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the ordinary shares of the Company, no par value (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Ordinary shares, no par value

     

    Item 2(e) CUSIP Number

     

    74638P109       The CUSIP Number applies to the American Depositary Shares, each of which represents one (1) Share.

     

     

     

     

    CUSIP No: 74638P109

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
       
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
       
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
       
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
       
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares (represented by American Depositary Shares) issuable upon the exercise of warrants to purchase American Depositary Shares.

     

    The Company’s Proxy Statement, filed on October 22, 2020, indicates there were 172,105,742 Shares outstanding as of October 20, 2020.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 74638P109

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [x]

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 74638P109

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021    
         
         
    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of   Name:  Brian Sopinsky
    Attorney, a copy of which was   Title:  Secretary
    previously filed      
       
    By: /s/ Brian Sopinsky    
    Name:  Brian Sopinsky    
    Title:  Secretary    
             

     

     

     

    CUSIP No: 74638P109

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         
         

    *Previously filed

     

     

     

    Get the next $PPBT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PPBT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PPBT
    Financials

    Live finance-specific insights

    See more
    • Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

      Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the year and the three months ended December 31, 2022. "We are reporting our 2022 financial results which are in line with our plans," said Gil Efron, Chief Executive Officer of Purple Biotech. "Our end-of-y

      2/8/23 7:12:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PPBT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

      REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon, Portugal from June 16-19, 2025. "Purple's proprietary CAPTN-3 platform of T-cell engagers enables the creation of a large number of antibodies to different targets, and by capping the anti-CD3 a

      6/23/25 7:00:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

      Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor resistance REHOVOT, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the initiation of a Phase 2 clinical study evaluating NT219 in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). NT219 is a novel small molecule designed to target

      6/17/25 7:00:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

      REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced a poster presentation on its novel CAPTN-3 tri-specific antibody platform, will be featured at the Annual Congress of the European Association for Cancer Research (EACR) 2025, being held in Lisbon, Portugal from June 16 – 19, 2025. EACR poster details are as follows: Abstract #: EACR25-1964Title: "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers"Session Title: ImmunotherapySession Date and T

      6/4/25 7:00:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PPBT
    SEC Filings

    See more
    • SEC Form 6-K filed by Purple Biotech Ltd.

      6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

      6/23/25 7:06:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Purple Biotech Ltd.

      6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

      6/17/25 7:02:14 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Purple Biotech Ltd.

      6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

      5/21/25 7:12:52 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care